“I’m humbled and honoured by the award”, said Joseph Gabriele. “I’m grateful to the Delivra team who are the true heroes. I’m proud that EY has recognized the capabilities of our unique patented delivery system, DelivraTM, for pharmaceutical and natural molecules across a spectrum of medical and consumer products capabilities. Delivra was born out of a need to help my wife who was debilitated by post-surgery pain, hence the genesis of our novel topical solution. She feared the addictive powers of opioids and couldn’t take oral medications due to digestive challenges. Today, Delivra helps many pain suffers in Canada and internationally. We also have an over-the-counter product line, called LivReliefTM, and just launched a new Extra Strength Chronic Angry Pain cream, as well as a unique new Sports & Active cream. In our pharmaceutical division, we are helping patients that are suffering with pain related to medical issues, including diabetes, and we have the capability of delivering cannabis and CBD to both humans and animals, topically and effectively. Our mission is to help pain sufferers reclaim their lives back. We are excited about the future and our proven capability and potential to help millions of people.”
“Companies in the health care sector face a challenging and competitive landscape,” says Paula Smith, EY Entrepreneur Of The Year Ontario Program Co-Director. “Canada, in particular, has an aging population and growing demand for patient care, pushing entrepreneurs to respond quickly and thoughtfully with innovative solutions to meet changing needs.”
“Delivra is doing just that,” adds Elena Doucette, EY Entrepreneur Of The Year Ontario Program Co-Director. “They’re revolutionizing the delivery of pain relief, and doing it in a safer and more effective way for those in need. We’re proud to have recognized the outstanding work Joseph is doing in the health care sector.”
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. LivReliefTM products are available in pharmacies, grocery chains, and independent health food stores across Canada, including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, Prince Edward Island.
About EY Entrepreneur Of The Year®
EY Entrepreneur Of The Year® is the world’s most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 50 countries. ey.com/ca/EOY
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Dr. Joseph Gabriele
Chief Executive Officer